INmune Bio (INMB) Stock Forecast, Price Target & Predictions
INMB Stock Forecast
INmune Bio stock forecast is as follows: an average price target of $22.00 (represents a 302.93% upside from INMB’s last price of $5.46) and a rating consensus of 'Buy', based on 1 wall street analysts offering a 1-year stock forecast.
INMB Price Target
INMB Analyst Ratings
INmune Bio Price Target by Analyst
Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
---|---|---|---|---|---|---|
Aug 22, 2024 | George Farmer | Scotiabank | $22.00 | $6.85 | 221.17% | 302.93% |
INmune Bio Price Target by Period
1M | 3M | 12M | |
---|---|---|---|
# Anlaysts | 1 | 1 | 1 |
Avg Price Target | $22.00 | $22.00 | $22.00 |
Last Closing Price | $5.46 | $5.46 | $5.46 |
Upside/Downside | 302.93% | 302.93% | 302.93% |
Analyst Ratings Upgrades/Downgrades
Date | Company | Previous Rating | New Rating | Rating Change |
---|---|---|---|---|
Aug 21, 2024 | Scotiabank | - | Outperform | Initialise |
INmune Bio Financial Forecast
INmune Bio Revenue Forecast
Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Sep 22 | Mar 22 | Sep 21 | Mar 21 | Mar 19 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | - | - | - | - | $-282.00K | $43.00K | $46.00K | $98.00K | $163.00K | $14.00K | $4.00K | - |
Avg Forecast | $14.00K | $14.00K | $14.00K | $28.00K | $43.00K | $46.00K | $38.00K | $906.95K | $226.67K | $1.45M | $3.26K | $83.50K |
High Forecast | $14.00K | $14.00K | $14.00K | $28.00K | $43.00K | $46.00K | $38.00K | $1.09M | $272.00K | $1.45M | $3.91K | $83.50K |
Low Forecast | $14.00K | $14.00K | $14.00K | $28.00K | $43.00K | $46.00K | $38.00K | $725.56K | $181.34K | $1.45M | $2.61K | $83.50K |
# Analysts | 1 | 3 | 1 | - | 1 | - | - | 13 | 17 | 8 | 10 | 8 |
Surprise % | - | - | - | - | -6.56% | 0.93% | 1.21% | 0.11% | 0.72% | 0.01% | 1.23% | - |
INmune Bio EBITDA Forecast
Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Sep 22 | Mar 22 | Sep 21 | Mar 21 | Mar 19 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 3 | 1 | - | 1 | - | - | 13 | 17 | 8 | 10 | 8 |
EBITDA | - | - | - | - | $45.07M | $-8.53M | $-6.41M | $-7.44M | $-6.48M | $-9.46M | $-4.56M | $-1.90M |
Avg Forecast | $-11.59K | $-11.59K | $-11.59K | $-23.18K | $-35.60K | $-38.08K | $-31.46K | $-6.38M | $-9.60M | $-1.20M | $-3.71M | $-1.81M |
High Forecast | $-11.59K | $-11.59K | $-11.59K | $-23.18K | $-35.60K | $-38.08K | $-31.46K | $-5.10M | $-7.68M | $-1.20M | $-2.97M | $-1.45M |
Low Forecast | $-11.59K | $-11.59K | $-11.59K | $-23.18K | $-35.60K | $-38.08K | $-31.46K | $-7.65M | $-11.52M | $-1.20M | $-4.45M | $-2.17M |
Surprise % | - | - | - | - | -1266.10% | 223.93% | 203.78% | 1.17% | 0.67% | 7.88% | 1.23% | 1.05% |
INmune Bio Net Income Forecast
Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Sep 22 | Mar 22 | Sep 21 | Mar 21 | Mar 19 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 3 | 1 | - | 1 | - | - | 13 | 17 | 8 | 10 | 8 |
Net Income | - | - | - | - | $51.72M | $-8.56M | $-6.50M | $-8.01M | $-7.33M | $-9.46M | $-4.56M | $-1.90M |
Avg Forecast | $-11.01M | $-10.67M | $-12.16M | $-10.33M | $-8.24M | $-7.59M | $-7.65M | $-6.38M | $-9.60M | $-7.00M | $-3.71M | $-1.80M |
High Forecast | $-11.01M | $-10.28M | $-12.16M | $-10.33M | $-6.55M | $-7.59M | $-7.65M | $-5.10M | $-7.68M | $-7.00M | $-2.97M | $-1.44M |
Low Forecast | $-11.01M | $-11.06M | $-12.16M | $-10.33M | $-9.92M | $-7.59M | $-7.65M | $-7.65M | $-11.52M | $-7.00M | $-4.45M | $-2.16M |
Surprise % | - | - | - | - | -6.28% | 1.13% | 0.85% | 1.26% | 0.76% | 1.35% | 1.23% | 1.06% |
INmune Bio SG&A Forecast
Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Sep 22 | Mar 22 | Sep 21 | Mar 21 | Mar 19 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 3 | 1 | - | 1 | - | - | 13 | 17 | 8 | 10 | 8 |
SG&A | - | - | - | - | $2.40M | $2.59M | $2.31M | $2.38M | $2.33M | $2.52M | $2.06M | $1.81M |
Avg Forecast | $2.00M | $2.00M | $2.00M | $4.00M | $6.15M | $6.57M | $5.43M | $129.61M | $32.39M | $207.22M | $465.74K | $11.93M |
High Forecast | $2.00M | $2.00M | $2.00M | $4.00M | $6.15M | $6.57M | $5.43M | $155.54M | $38.87M | $207.22M | $558.64K | $11.93M |
Low Forecast | $2.00M | $2.00M | $2.00M | $4.00M | $6.15M | $6.57M | $5.43M | $103.69M | $25.91M | $207.22M | $372.57K | $11.93M |
Surprise % | - | - | - | - | 0.39% | 0.39% | 0.43% | 0.02% | 0.07% | 0.01% | 4.43% | 0.15% |
INmune Bio EPS Forecast
Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Sep 22 | Mar 22 | Sep 21 | Mar 21 | Mar 19 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 3 | 1 | - | 1 | - | - | 13 | 17 | 8 | 10 | 8 |
EPS | - | - | - | - | $1.21 | $-0.00 | $-0.00 | $-0.45 | $-0.41 | $-0.55 | $-0.32 | $-0.20 |
Avg Forecast | $-0.57 | $-0.55 | $-0.63 | $-0.54 | $-0.43 | $-0.39 | $-0.40 | $-0.53 | $-0.57 | $-0.36 | $-0.27 | $-0.19 |
High Forecast | $-0.57 | $-0.53 | $-0.63 | $-0.54 | $-0.34 | $-0.39 | $-0.40 | $-0.53 | $-0.57 | $-0.36 | $-0.27 | $-0.19 |
Low Forecast | $-0.57 | $-0.57 | $-0.63 | $-0.54 | $-0.51 | $-0.39 | $-0.40 | $-0.53 | $-0.57 | $-0.36 | $-0.27 | $-0.19 |
Surprise % | - | - | - | - | -2.84% | 0.00% | 0.00% | 0.86% | 0.72% | 1.52% | 1.17% | 1.05% |
INmune Bio Peer Comparison by Price Target
Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
---|---|---|---|---|---|
INAB | IN8bio | $0.32 | $14.00 | 4275.00% | Buy |
CUE | Cue Biopharma | $0.59 | $5.00 | 747.46% | Buy |
ANTX | AN2 Therapeutics | $1.04 | $8.75 | 741.35% | Buy |
PYPD | PolyPid | $3.47 | $25.00 | 620.46% | Buy |
AVTE | Aerovate Therapeutics | $1.90 | $13.00 | 584.21% | Hold |
INMB | INmune Bio | $5.46 | $22.00 | 302.93% | Buy |
DRMA | Dermata Therapeutics | $1.58 | $6.00 | 279.75% | Buy |
ANEB | Anebulo Pharmaceuticals | $2.08 | $6.00 | 188.46% | Buy |
ANIX | Anixa Biosciences | $3.35 | $8.00 | 138.81% | Buy |
TCRX | TScan Therapeutics | $5.74 | $12.00 | 109.06% | Buy |
AVXL | Anavex Life Sciences | $5.31 | $11.00 | 107.16% | Buy |
ELYM | Eliem Therapeutics | $8.46 | $13.00 | 53.66% | Buy |
INMB Forecast FAQ
Is INmune Bio a good buy?
Yes, according to 1 Wall Street analysts, INmune Bio (INMB) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 100.00% of INMB's total ratings.
What is INMB's price target?
INmune Bio (INMB) average price target is $22 with a range of $22 to $22, implying a 302.93% from its last price of $5.46. The data is based on 1 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will INmune Bio stock go up soon?
According to Wall Street analysts' prediction for INMB stock, the company can go up by 302.93% (from the last price of $5.46 to the average price target of $22), up by 302.93% based on the highest stock price target, and up by 302.93% based on the lowest stock price target.
Can INmune Bio stock reach $8?
INMB's average twelve months analyst stock price target of $22 supports the claim that INmune Bio can reach $8 in the near future.
What is INmune Bio's current price target trend?
1 Wall Street analyst forecast a $22 price target for INmune Bio (INMB) this month, up 302.93% from its last price of $5.46. Compared to the last 3 and 12 months, the average price target increased by 302.93% and increased by 302.93%, respectively.
What are INmune Bio's analysts' financial forecasts?
INmune Bio's analysts financial forecasts for the fiscal year (Dec 2023) are as follows: average revenue is $127K (high $127K, low $127K), average EBITDA is $-105K (high $-105K, low $-105K), average net income is $-23.487M (high $-21.802M, low $-25.172M), average SG&A $18.15M (high $18.15M, low $18.15M), and average EPS is $-1.216 (high $-1.129, low $-1.304). INMB's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $70K (high $70K, low $70K), average EBITDA is $-57.951K (high $-57.951K, low $-57.951K), average net income is $-44.166M (high $-43.778M, low $-44.553M), average SG&A $10M (high $10M, low $10M), and average EPS is $-2.288 (high $-2.267, low $-2.308).
Did the INMB's actual financial results beat the analysts' financial forecasts?
Based on INmune Bio's last annual report (Dec 2023), the company's revenue was $-155K, which missed the average analysts forecast of $127K by -222.05%. Apple's EBITDA was $30.01M, missing the average prediction of $-105K by -28640.45%. The company's net income was $30.01M, missing the average estimation of $-23.487M by -227.77%. Apple's SG&A was $9.62M, missing the average forecast of $18.15M by -46.98%. Lastly, the company's EPS was $0, missing the average prediction of $-1.216 by -100.00%. In terms of the last quarterly report (Dec 2023), INmune Bio's revenue was $-282K, missing the average analysts' forecast of $43K by -755.81%. The company's EBITDA was $45.07M, missing the average prediction of $-35.599K by -126710.30%. INmune Bio's net income was $51.72M, missing the average estimation of $-8.238M by -727.85%. The company's SG&A was $2.4M, missing the average forecast of $6.15M by -60.94%. Lastly, the company's EPS was $1.21, missing the average prediction of $-0.427 by -383.59%